Generer rapport
Ossiform Aps
Oslogade 1, 5000 Odense C, CVR 38838512
Virksomhedsform
Anpartsselskab
Etableret
2017
Størrelse
Små
Ansatte
20
Omsætning
-
DKK
Bruttofortj.
-7.728.744
DKK
Primært resultat (EBIT)
-17.168.647
DKK
Årets resultat
-15.030.850
DKK
Egenkapital
17
MDKK
Reklamebeskyttet virksomhed
Denne virksomhed er reklamebeskyttet. Det betyder bl.a. at oplysningerne ikke må bruges til reklamehenvendelser. annonce
Flere nøgletal og analyser?
Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!
Rang Årets resultat
Rang i branche
583/613
"Bund 10%"
Rang i Danmark
340.807/344.160
"Bund 10%"
Direktion top 3
| Thea Olesen 3 | Direktør |
Bestyrelse top 3
| Mette-Marie Sonne Harild 3 | Bestyrelsesformand |
| Henrik Busch-Larsen 8 | Bestyrelsesmedlem |
| Martin Lavesen 49 | Bestyrelsesmedlem |
Legale ejere top 3
| 100% | Ossiform Limited | GB |
Tegningsregler
Virksomheden tegnes af direktionen
Stamoplysninger baseret på CVR
| Navn | Ossiform Aps |
| Binavne | Ossiform Denmark Aps, P3D Bone Aps, Particle3D Aps, We Print Bone Aps Vis mere |
| CVR | 38838512 |
| Adresse | Oslogade 1, 5000 Odense C |
| Branche | Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik [721900] |
| Web | particle3d.com |
| Etableret | 07-08-2017 (6 år) |
| Første regnskabsperiode | 07-08-2017 til 31-12-2018 |
| Virksomhedsform | Anpartsselskab |
| Antal ansatte | 20 (årsværk:15) |
| Reklamebeskyttelse | Ja |
| Revisor | Beierholm, Statsautoriseret Revisionspartnerselskab siden 31-10-2018 |
| Regnskabsperiode | 01-01 til 31-12 |
| Selskabskapital | 137.500 DKK 130.000 DKK (25-01-2023 - 24-04-2024) 110.000 DKK (15-11-2021 - 24-01-2023) 100.000 DKK (29-09-2020 - 14-11-2021) 75.833 DKK (26-08-2019 - 28-09-2020) 67.210 DKK (25-04-2019 - 25-08-2019) |
| Vedtægter seneste | 25-04-2024 |
Medlem af brancherne
- Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknikNACE6 indeholdende 1.213 virk.
- Forskning og eksperimentel udvikling indenfor naturvidenskab og teknikNACE3 indeholdende 1.771 virk.
- Videnskabelig forskning og udviklingNACE2 indeholdende 2.064 virk.
- Liberale, videnskabelige og tekniske tjenesteydelserNACE1 indeholdende 86.889 virk.
Formål
Selskabets formål er udvikle og bringe 3D printede produkter på markedet.
Regnskab
| 2023 | 2022 | 2021 | |
|---|---|---|---|
| Valuta/enhed | 000' DKK | 000' DKK | 000' DKK |
| Omsætning | - - | - - | - - |
| Bruttofortjeneste | -7.729 - | -6.143 - | -3.916 - |
| Årets resultat | -15.031 - | -11.740 - | -7.385 - |
| Egenkapital | 17.205 - | -1.765 - | 9.975 -12% |
| Balance | 19.361 +88% | 10.276 -4% | 10.689 -11% |
Ledelsesberetning
Development in activities and financial affairs
The income statement for the period 01.01.23 - 31.12.23 shows a loss of DKK -15,030,850 against DKK -11,739,579 for the period 01.01.22 - 31.12.22. The balance sheet shows equity of DKK 17,204,519.
Among key achievements in 2023, are submitting the FDA application for the P3D Bone, optimization of production processes, preparing for and initiating the ISO 13485 certification audits, forming the market access strategy for the next generation product, the P3D Bone spine implant, as well as identifying potential partners to be able to provide fully resorbable solutions.
Highly skilled US advisors and KOLs are hired to give guidance on clinical use, to form and implement the market access strategy, to connect to first-class hospitals and plan for first in human under the US registry study.
As Point of Care (POC) printing of medical devices gathers more attention and is slowly proving to be the future of medical device production, the company has taken the first steps to ensure that the unique P3D Bone Material is useable in partner printer setups for a POC solution. A strategic partnership is entered with Cellink – a leading 3D bioprinting company and provider of bioprinters – to launch Ossi Ink, a ready-to-print bioink based on Ossiform’s biomaterial.
Patents protecting the essential part of the innovation to 3D print the P3D Bone have been granted in most of the world and the royalty payment to the University of Southern Denmark has ended as the buy-out clause has been effectuated and the final amount has been paid to the University.
Trademarks have been granted in Europe and the US for the Ossiform name.
Information on going concern
The company's planned activities for 2024 bring a need for additional capital in 2024. Short term capital will be transferred from the holding company Ossiform ltd sufficient to support activities until the end of 2024. Also, the management of the Ossiform group has received a draft agreement with Westhill Capital in London regarding a bridge funding of £2M. The management expects that the Ossiform group will be secured new capital in the first half of 2024 and thus presents the financial statements under the going concern assumption. To secure that suffecinet cash will be transferred from Ossiform Ltd, the management of Ossifrom Ltd has signed a letter of support for the financial year 2024.
The income statement for the period 01.01.23 - 31.12.23 shows a loss of DKK -15,030,850 against DKK -11,739,579 for the period 01.01.22 - 31.12.22. The balance sheet shows equity of DKK 17,204,519.
Among key achievements in 2023, are submitting the FDA application for the P3D Bone, optimization of production processes, preparing for and initiating the ISO 13485 certification audits, forming the market access strategy for the next generation product, the P3D Bone spine implant, as well as identifying potential partners to be able to provide fully resorbable solutions.
Highly skilled US advisors and KOLs are hired to give guidance on clinical use, to form and implement the market access strategy, to connect to first-class hospitals and plan for first in human under the US registry study.
As Point of Care (POC) printing of medical devices gathers more attention and is slowly proving to be the future of medical device production, the company has taken the first steps to ensure that the unique P3D Bone Material is useable in partner printer setups for a POC solution. A strategic partnership is entered with Cellink – a leading 3D bioprinting company and provider of bioprinters – to launch Ossi Ink, a ready-to-print bioink based on Ossiform’s biomaterial.
Patents protecting the essential part of the innovation to 3D print the P3D Bone have been granted in most of the world and the royalty payment to the University of Southern Denmark has ended as the buy-out clause has been effectuated and the final amount has been paid to the University.
Trademarks have been granted in Europe and the US for the Ossiform name.
Information on going concern
The company's planned activities for 2024 bring a need for additional capital in 2024. Short term capital will be transferred from the holding company Ossiform ltd sufficient to support activities until the end of 2024. Also, the management of the Ossiform group has received a draft agreement with Westhill Capital in London regarding a bridge funding of £2M. The management expects that the Ossiform group will be secured new capital in the first half of 2024 and thus presents the financial statements under the going concern assumption. To secure that suffecinet cash will be transferred from Ossiform Ltd, the management of Ossifrom Ltd has signed a letter of support for the financial year 2024.
06-03-2024